These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1590998)

  • 1. Tumor antigens.
    Urban JL; Schreiber H
    Annu Rev Immunol; 1992; 10():617-44. PubMed ID: 1590998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy.
    Sensi M; Anichini A
    Clin Cancer Res; 2006 Sep; 12(17):5023-32. PubMed ID: 16951217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.
    Toes RE; Offringa R; Feltkamp MC; Visseren MJ; Schoenberger SP; Melief CJ; Kast WM
    Behring Inst Mitt; 1994 Jul; (94):72-86. PubMed ID: 7998917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant ras epitopes as targets for cancer vaccines.
    Abrams SI; Hand PH; Tsang KY; Schlom J
    Semin Oncol; 1996 Feb; 23(1):118-34. PubMed ID: 8607022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives].
    Gaugler B; Olive D
    Pathol Biol (Paris); 1998 Dec; 46(10):771-8. PubMed ID: 9922993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-specific antigens revisited: presentation to the immune system of fusion peptides resulting solely from tumor-specific chromosomal translocations.
    Pawelec G; Kalbacher H; Bruserud O
    Oncol Res; 1992; 4(8-9):315-20. PubMed ID: 1486216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Human tumor-rejection antigens and peptides from genes to clinical research].
    Itoh K; Yamana H; Shichijo S; Yamada A
    Nihon Geka Gakkai Zasshi; 2000 Sep; 101(9):612-7. PubMed ID: 11022676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.
    Rosenberg SA
    Annu Rev Med; 1996; 47():481-91. PubMed ID: 8712798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor antigens recognized by T lymphocytes.
    Boon T; Cerottini JC; Van den Eynde B; van der Bruggen P; Van Pel A
    Annu Rev Immunol; 1994; 12():337-65. PubMed ID: 8011285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Identification of cancer antigens of relevance for specific cancer immunotherapy].
    van den Eynde B
    Bull Mem Acad R Med Belg; 2001; 156(10-12):548-55. PubMed ID: 12371273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique tumor antigens redefined as mutant tumor-specific antigens.
    Mumberg D; Wick M; Schreiber H
    Semin Immunol; 1996 Oct; 8(5):289-93. PubMed ID: 8956457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigens recognized on human tumors by cytolytic T lymphocytes: towards vaccination?
    Coulie PG
    Stem Cells; 1995 Jul; 13(4):393-403. PubMed ID: 7549898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation in the immunodominant epitope of the HPV16 E7 oncoprotein as a mechanism of tumor escape.
    Smahel M; Tejklova P; Smahelova J; Polakova I; Mackova J
    Cancer Immunol Immunother; 2008 Jun; 57(6):823-31. PubMed ID: 17962940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
    Knutson KL; Disis ML
    Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor antigens].
    Tiuriaeva II
    Tsitologiia; 2008; 50(3):189-209. PubMed ID: 18664121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenic HER-2/neu peptides as tumor vaccines.
    Baxevanis CN; Sotiriadou NN; Gritzapis AD; Sotiropoulou PA; Perez SA; Cacoullos NT; Papamichail M
    Cancer Immunol Immunother; 2006 Jan; 55(1):85-95. PubMed ID: 15948002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.